GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » E10

Swedish Orphan Biovitrum AB (OSTO:SOBI) E10 : kr8.02 (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Sep. 2024 was kr4.220. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr8.02 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Swedish Orphan Biovitrum AB's average E10 Growth Rate was 18.50% per year. During the past 3 years, the average E10 Growth Rate was 25.80% per year. During the past 5 years, the average E10 Growth Rate was 37.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Swedish Orphan Biovitrum AB was 117.50% per year. The lowest was 25.80% per year. And the median was 41.60% per year.

As of today (2024-12-14), Swedish Orphan Biovitrum AB's current stock price is kr315.20. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Sep. 2024 was kr8.02. Swedish Orphan Biovitrum AB's Shiller PE Ratio of today is 39.30.

During the past 13 years, the highest Shiller PE Ratio of Swedish Orphan Biovitrum AB was 544.45. The lowest was 28.96. And the median was 44.66.


Swedish Orphan Biovitrum AB E10 Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB E10 Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 3.60 4.61 6.10 7.16

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.77 7.16 7.57 7.65 8.02

Competitive Comparison of Swedish Orphan Biovitrum AB's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.



Swedish Orphan Biovitrum AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=4.22/132.3043*132.3043
=4.220

Current CPI (Sep. 2024) = 132.3043.

Swedish Orphan Biovitrum AB Quarterly Data

per share eps CPI Adj_EPS
201412 -0.067 100.225 -0.088
201503 0.267 99.950 0.353
201506 -0.010 99.995 -0.013
201509 0.019 100.228 0.025
201512 -0.048 100.276 -0.063
201603 1.070 100.751 1.405
201606 1.098 101.019 1.438
201609 0.478 101.138 0.625
201612 0.267 102.022 0.346
201703 0.716 102.022 0.929
201706 0.936 102.752 1.205
201709 1.146 103.279 1.468
201712 1.261 103.793 1.607
201803 1.815 103.962 2.310
201806 2.417 104.875 3.049
201809 2.197 105.679 2.751
201812 2.092 105.912 2.613
201903 2.980 105.886 3.723
201906 1.614 106.742 2.001
201909 1.748 107.214 2.157
201912 4.394 107.766 5.395
202003 3.802 106.563 4.720
202006 0.907 107.498 1.116
202009 0.888 107.635 1.092
202012 4.805 108.296 5.870
202103 2.226 108.360 2.718
202106 0.860 108.928 1.045
202109 1.519 110.338 1.821
202112 3.993 112.486 4.697
202203 1.748 114.825 2.014
202206 0.821 118.384 0.918
202209 1.420 122.296 1.536
202212 4.450 126.365 4.659
202303 3.400 127.042 3.541
202306 0.710 129.407 0.726
202309 0.300 130.224 0.305
202312 3.000 131.912 3.009
202403 2.330 132.205 2.332
202406 0.650 132.716 0.648
202409 4.220 132.304 4.220

Add all the adjusted EPS together and divide 10 will get our e10.


Swedish Orphan Biovitrum AB  (OSTO:SOBI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Swedish Orphan Biovitrum AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=315.20/8.02
=39.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Swedish Orphan Biovitrum AB was 544.45. The lowest was 28.96. And the median was 44.66.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Swedish Orphan Biovitrum AB E10 Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines